Avapritinib
Solid Tumor, Unspecified, Child
Blueprint Medicines CorporationSmall moleculePhase 1/2Active
CCC
52/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Solid Tumor, Unspecified, Child cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
2-HYDROXYOLEIC ACID (SODIUM SALT) Laminar Pharmaceuticals | Phase 1/2 | CCC |
Same molecule, other indications
Avapritinib is also rated in:
systemic mastocytosis with an associated clonal hematologic non-mast cell lineage diseaseDormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →